MedBioSphere
Articles Videos The Web  
    

Sheffield Medical Technologies

Selected Abstract

Sheffield Medical Technologies Initiates Phase I/II Human Clinical Trial for Clotrimazole
Receives Patent for Use of Topical Clotrimazole For Treatment of Actinic Keratosis NEW YORK, Sept. 19 /PRNewswire/ -- Ion Pharmaceuticals, Inc., a wholly owned subsidiary of Sheffield Medical Technologies, Inc. (AMEX: SHM) announced today that it has initiated a Phase I/II human clinical trial of ...
September 19, 1996; PR Newswire

Read the full article with a free-trial membership at HighBeam Research



Related Articles

1. SHEFFIELD MEDICAL TECHNOLOGIES REPORTS FIRST QUARTER FINANCIAL RESULTS
2. Sheffield Medical Technologies Reports Second Quarter Financial Results
3. edical Technologies Reports First Quarter Financial Results
4. SHEFFIELD MEDICAL TECHNOLOGIES INC. REPORTS 1995 THIRD QUARTER RESULTS
5. SHEFFIELD MEDICAL TECHNOLOGIES REPORTS FOURTH QUARTER AND YEAR-END FINANCIAL RESULTS
6. Sheffield Medical Technologies Reports Financial Results and Highlights Third Quarter Progress
7. Sheffield Medical Technologies Completes Private Placement
8. SHEFFIELD MEDICAL TECHNOLOGIES AND SEQUUS PHARMACEUTICALS SIGN OPTION AGREEMENT FOR LICENSE TO DEVELOP AND COMMERCIALIZE NEW HIV/AIDS THERAPEUTIC
9. Sheffield Medical Technologies Names Thomas M. Fitzgerald President
10. SHEFFIELD MEDICAL TECHNOLOGIES FORMS SUBSIDIARY TO ADVANCE ANTI- PROLIFERATIVE DRUG PROGRAM